Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Moffitt Cancer Center

Sites in Tampa, FL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 2:32 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
713
Shown on this page
12
Current sort
Recently updated
Campus scope
Moffitt Cancer Center, Tampa, FL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Moffitt Cancer Center, Tampa, FL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 613–624 of 713 matching trials with a site at Moffitt Cancer Center, Tampa, FL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 2 Interventional

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

NCT04858256
Status at this site: Not yet recruiting
View directory record Official record
Conditions
T-Cell Neoplasm, Lymphoproliferative Disorders
Interventions
Pacritinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Duarte, California • Tampa, Florida • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Nov 1, 2026, 2:32 AM EST
Recruiting No phase listed Observational

A First-in-Human Study of FID-022 in Solid Tumor Patients

NCT07249775
Status at this site: Recruiting
View directory record Official record
Conditions
Pancreatic Cancer, Cancer Cachexia
Interventions
Baseline Lifestyle and Symptom Assessment, Extended Lifestyle Monitoring, Feasibility Survey
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Nov 1, 2026, 2:32 AM EST
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

NCT03468218
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Unresectable Head and Neck Squamous Cell Carcinoma
Interventions
Cabozantinib, Pembrolizumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Nov 1, 2026, 2:32 AM EST
Active, not recruiting Phase 3 Interventional Results available

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

NCT01208662
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Bortezomib, Dexamethasone, Autologous Stem Cell Transplant
Drug · Procedure
Lead sponsor
Paul Richardson, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Nov 1, 2026, 2:32 AM EST
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488
Site status not listed — check the official record
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Nov 1, 2026, 2:32 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Development of a Mindfulness-Based Smartphone Application for BMT Caregivers

NCT07352943
Site status not listed — check the official record
View directory record Official record
Conditions
Caregivers of Hematopoietic Stem Cell Transplant (HCT) Patients
Interventions
App
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Nov 1, 2026, 2:32 AM EST
Active, not recruiting Phase 2 Interventional

SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

NCT03546582
Site status not listed — check the official record
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Pembrolizumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
15
States / cities
Tucson, Arizona • Tampa, Florida • Weston, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Nov 1, 2026, 2:32 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Communication Skills Intervention to Promote Transition Into Survivorship

NCT01483664
Site status not listed — check the official record
View directory record Official record
Conditions
Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
9
States / cities
Tampa, Florida • Basking Ridge, New Jersey • Brooklyn, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Nov 1, 2026, 2:32 AM EST
Active, not recruiting Phase 2 Interventional

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

NCT00335816
Site status not listed — check the official record
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiation therapy, laboratory biomarker analysis, DNA analysis, polymerase chain reaction, immunohistochemistry staining method
Drug · Procedure · Radiation + 2 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
14
States / cities
Concord, California • Duarte, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Nov 1, 2026, 2:32 AM EST
Active, not recruiting Phase 3 Interventional Results available

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

NCT04647526
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
[Lu-177]-PNT2002, Abiraterone, Enzalutamide
Drug
Lead sponsor
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
33
States / cities
Tucson, Arizona • Los Angeles, California • Newport Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Nov 1, 2026, 2:32 AM EST
Active, not recruiting Phase 2 Interventional

Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer

NCT03171025
Site status not listed — check the official record
View directory record Official record
Conditions
Bladder Cancer
Interventions
Nivolumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Nov 1, 2026, 2:32 AM EST
Active, not recruiting Phase 2 Interventional

Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

NCT04572815
Site status not listed — check the official record
View directory record Official record
Conditions
Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm
Interventions
Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Ustekinumab
Drug · Other · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Duarte, California • Tampa, Florida • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Nov 1, 2026, 2:32 AM EST

About this Moffitt Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list Moffitt Cancer Center in Tampa, FL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.